Objectives: To establish the efficacy of oral rapamycin at a dose of 2 mg for 1 month at
reducing the 6-month restenosis rate after the implantation of bare metal stents. Methods: A …

Objectives: The aim of this study was to assess the role of short oral administration of
rapamycin, without loading dose, in the reduction of restenosis rate after bare metal stent …

Objectives: The purpose of this study was to assess the role of oral rapamycin in decreased
restenosis after bare metal stent implantation. Background: Small observational studies …

BACKGROUND: Recent human trials with rapamycin-eluting stents have shown very low
restenosis rates. However, the high costs of these devices preclude their use in routine …

Objectives: The aim of this study was to establish safety and feasibility of oral Rapamycin at
two doses—2 mg and 5 mg—in achieving low rates of repeat target lesion revascularization …

Objective: To assess the role of oral rapamycin in the prevention of coronary restenosis in
patients undergoing coronary stenting. Methods: From December 2001 through February …

Rapamycin-coated stents are associated with low restenosis rates, but the ability of oral
rapamycin to prevent restenosis is unknown. From December 2001 through February 2002 …

Background—Restenosis after implantation of drug-eluting stents (DES) is a rare
phenomenon, occurring more frequently peri-stent. Methods and Results—We evaluated the …

Objectives: This study aimed to assess the efficacy of a rapamycin plus 17-β-estradiol–
eluting stent versus a rapamycin-eluting stent in patients with coronary artery disease …

Background: Drug-eluting stent (DES) platforms devoid of durable polymer have potential to
enhance long-term safety outcomes. The ISAR-TEST-3 study was a randomised trial …